With 65688.0 shares changed hands, the volume of the stock remained lighter than its average volume of 0.18 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $12.345 whereas the lowest price it dropped to was $11.85. The 52-week range on BBOT shows that it touched its highest point at $14.87 and its lowest point at $8.50 during that stretch. It currently has a 1-year price target of $23.33. Beta for the stock currently stands at 0.14.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BBOT was up-trending over the past week, with a rise of 6.74%, but this was down by -0.73% over a month. Three-month performance surged to 3.21% while six-month performance rose 14.55%. The stock gained 16.19% in the past year, while it has gained 17.03% so far this year.
Float and Shares Shorts:
At present, 79.20 million BBOT shares are outstanding with a float of 43.55 million shares on hand for trading. On 2025-11-28, short shares totaled 1.13 million, which was 140.99999 higher than short shares on 1761868800. In addition to Mr. Eli M. Wallace Ph.D. as the firm’s CEO & Director, Dr. Pedro J. Beltran M.D., Ph.D. serves as its Chief Scientific Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, BBOT reported revenue of $0.0 and operating income of -$49181000.0. The EBITDA in the recently reported quarter was -$49000000.0 and diluted EPS was -$1.03.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With BBOT analysts setting a high price target of 27.0 and a low target of 20.0, the average target price over the next 12 months is 23.33333. Based on these targets, BBOT could surge 121.31% to reach the target high and rise by 63.93% to reach the target low. Reaching the average price target will result in a growth of 91.26% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$268.55813 being high and -$268.55813 being low. For BBOT, this leads to a yearly average estimate of -$268.55813.
